Clinical Trial Update: Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia [Phase 3]

View source ↗

Summary

An extension study of herombopag in pediatric patients with chronic immune thrombocytopenia is being conducted (Phase 3).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Herombopag (herombopag)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Immune Thrombocytopenia | Phase 3 | Status: UNKNOWN